Fresh Off Merger, Tekmira Posts Drop in Q2 Losses, Says New Delivery Deals on Horizon

Having settled a legal dispute over its core siRNA delivery technology by merging with Protiva Biotherapeutics, Tekmira sees licensing deals for the technology, including a possible one with Takeda, as providing near-term revenues.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.